Anemia in Heart Failure. Marker or Mediator of Adverse Prognosis?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 51, Issue 5, 2008, Pages 577-578

  Levy, Wayne C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; IRON; PHOSPHOLIPASE A2;

ANEMIA; CORONARY ARTERY BYPASS GRAFT; EDITORIAL; HEART FAILURE; HUMAN; KIDNEY DISEASE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANEMIA; HEART FAILURE; HEMATINICS; HUMANS; IRON; PROGNOSIS;

EID: 38349173079     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.052     Document Type: Editorial

References (23)

1. Tennet J. The Poor Planter's Physician. 3rd edition (1736), William Parks, Williamsburg, VA
2. Anderson J.L., Ronnow B.S., Horne B.D., et al. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol 99 (2007) 169-174
3. Smebye M.L., Iversen E.K., Hoieggen A., et al. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). Am J Cardiol 100 (2007) 855-859
4. Collins A.J., Ma J.Z., and Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 20 (2000) 345-349
5. Sabatine M.S., Morrow D.A., Giugliano R.P., et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111 (2005) 2042-2049
6. Kulier A., Levin J., Moser R., et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 116 (2007) 471-479
7. Reinecke H., Trey T., Wellmann J., et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 24 (2003) 2142-2150
8. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
9. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113 (2006) 1424-1433
10. Tang W.H.W., Tong W., Jain A., Francis G.S., Harris C.M., and Young J.B. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 51 (2008) 569-576
11. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2118
12. Wiltink W.F., Ybema H.J., Leijnse B., and Gerbrandy J. The iron tolerance test. Measurement of absorption and utilization of a therapeutic dose of iron. Clin Chim Acta 13 (1966) 701-707
13. Jensen N.M., Brandsborg M., Boesen A.M., Yde H., and Dahlerup J.F. Low-dose oral iron absorption test in anaemic patients with and without iron deficiency determined by bone marrow iron content. Eur J Haematol 63 (1999) 103-111
14. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48 (2006) 1225-1227
15. Beck-da-Silva L., Rohde L.E., Pereira-Barretto A.C., et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 13 (2007) 14-17
16. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., and Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18 (2004) 1031-1033
17. The relationship between anemia and serum erythropoietin (EPO) concentrations: study of 176 patients with nonrenal anemias. http://depts.washington.edu/labweb/docs/EP.jpg Accessed August 31, 2007
18. Koury M.J., and Bondurant M.C. The mechanism of erythropoietin action. Am J Kidney Dis 18 (1991) 20-23
19. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
20. Parsa C.J., Kim J., Riel R.U., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279 (2004) 20655-20662
21. Burger D., Lei M., Geoghegan-Morphet N., Lu X., Xenocostas A., and Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72 (2006) 51-59
22. Abraham W., Klapholz M., Anand I., et al. The effect of darbepoetin alfa treatment on clinical outcomes in anemic patients with symptomatic heart failure: a preplanned pooled analysis of two randomized, double-blind placebo-controlled trials. Eur J Heart Fail 27 (2006) 166-167
23. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098